Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study of Early MIDAS Reduction at 3 Months as Predictor of Long-term Erenumab Treatment in Chronic Migraine: a Real-life, Open-label, Trial

NCT05442008 is registered in ClinicalTrials.gov with IRCCS National Neurological Institute "C. Mondino" Foundation as lead sponsor.

NCT NCT05442008
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05442008 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study of Early MIDAS Reduction at 3 Months as Predictor of Long-term Erenumab Treatment in Chronic Migraine: a Real-life, Open-label, Trial
Lead sponsor
IRCCS National Neurological Institute "C. Mondino" Foundation
Phase
Observational
Overall status
Completed
Start date
December 1, 2018
Completion date
January 1, 2021
Enrollment
53 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

migraine